Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 6/20 | 0.43 |
| ▸ | ACACB | O00763 | 8/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537937 | 1.00 | REN (0.43) | RENACACBUSP30 | |
| SCHEMBL4525082 | 1.00 | REN (0.43) | RENACACBUSP30 | |
| SCHEMBL4537941 | 1.00 | REN (0.43) | RENACACBUSP30 | |
| SCHEMBL4525078 | 1.00 | REN (0.43) | RENACACBUSP30 | |
| SCHEMBL4524734 | 0.82 | REN (0.46) | RENACACB | |
| SCHEMBL4524219 | 0.82 | REN (0.46) | RENACACB | |
| SCHEMBL3911301 | 0.82 | REN (0.46) | RENACACB | |
| SCHEMBL3921137 | 0.79 | REN (0.46) | RENACACB | |
| SCHEMBL3910660 | 0.79 | REN (0.46) | RENACACB | |
| SCHEMBL3919537 | 0.79 | REN (0.46) | RENACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | REN 1/4885ACACB 2551/4885USP30 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.